modelPiperacillinAndBetaLactamaseInhi

Diagram of PiperacillinAndBetaLactamaseInhi

Extends from Pharmacolibrary.Drugs.ATC.J.J01CR05.

Information

name:PiperacillinAndBetaLactamaseInhibitor
ATC code:J01CR05
route:intravenous
n-compartments2

Piperacillin is a broad-spectrum injectable penicillin-class antibiotic, usually co-administered with tazobactam, a beta-lactamase inhibitor. The combination is used for the treatment of moderate to severe bacterial infections including intra-abdominal, skin, gynecological, and nosocomial respiratory tract infections caused by susceptible organisms. This combination is approved and widely used today.

Pharmacokinetics

Pharmacokinetic parameters reported for piperacillin/tazobactam in healthy adult volunteers (mostly male and female, mean age ~29-35 years) after single intravenous dose.

References

  1. Chen, R, et al., & Wang, LY (2016). Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections. European journal of drug metabolism and pharmacokinetics 41(4) 363–372. DOI:10.1007/s13318-015-0276-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25894901

  2. Alobaid, AS, et al., & Roberts, JA (2017). Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. Antimicrobial agents and chemotherapy 61(3) –. DOI:10.1128/AAC.01276-16 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28052849

  3. Cojutti, PG, et al., & Pea, F (2024). Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing . Antimicrobial agents and chemotherapy 68(4) e0140423–None. DOI:10.1128/aac.01404-23 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38411995

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 initial generated model